<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">33718</article-id><article-id pub-id-type="doi">10.7554/eLife.33718</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group></article-categories><title-group><article-title>Hyperactivation of ERK by multiple mechanisms is toxic to RTK-RAS mutation-driven lung adenocarcinoma cells</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="author-101633"><name><surname>Unni</surname><given-names>Arun M</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-0530-1470</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-101634"><name><surname>Harbourne</surname><given-names>Bryant</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-101635"><name><surname>Oh</surname><given-names>Min Hee</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-101636"><name><surname>Wild</surname><given-names>Sophia</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-115344"><name><surname>Ferrarone</surname><given-names>John R</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-29158"><name><surname>Lockwood</surname><given-names>William W</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="corresp" rid="cor2">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-34804"><name><surname>Varmus</surname><given-names>Harold</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor3">*</xref><xref ref-type="other" rid="par-2"/><xref ref-type="other" rid="par-3"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><institution content-type="dept">Meyer Cancer Center</institution>, <institution>Weill Cornell Medicine</institution>, <addr-line><named-content content-type="city">New York</named-content></addr-line>, <country>United States</country></aff><aff id="aff2"><institution content-type="dept">Department of Integrative Oncology</institution>, <institution>British Columbia Cancer Agency</institution>, <addr-line><named-content content-type="city">Vancouver</named-content></addr-line>, <country>Canada</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-1062"><name><surname>Cooper</surname><given-names>Jonathan A.</given-names></name><role>Reviewing editor</role><aff><institution>Fred Hutchinson Cancer Research Center</institution>, <country>United States</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>aru2001@med.cornell.edu</email> (AU);</corresp><corresp id="cor2"><label>*</label>For correspondence: <email>wlockwood@bccrc.ca</email> (WL);</corresp><corresp id="cor3"><label>*</label>For correspondence: <email>varmus@med.cornell.edu</email> (HV);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>26</day><month>11</month><year>2018</year></pub-date><volume>7</volume><elocation-id>e33718</elocation-id><history><date date-type="received"><day>21</day><month>11</month><year>2017</year></date><date date-type="accepted"><day>26</day><month>11</month><year>2018</year></date></history><permissions><copyright-statement>Â© 2018, Unni et al</copyright-statement><copyright-year>2018</copyright-year><copyright-holder>Unni et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-33718-v1.pdf"/><abstract><p>Synthetic lethality results when mutant KRAS and EGFR proteins are co-expressed in human lung adenocarcinoma (LUAD) cells, revealing the biological basis for mutual exclusivity of <italic>KRAS </italic>and <italic>EGFR </italic>mutations. We have now defined the biochemical events responsible for the toxic effects by combining pharmacological and genetic approaches and to show that signaling through extracellular signal-regulated kinases (ERK1/2) mediates the toxicity. These findings imply that tumors with mutant oncogenes in the RAS pathway must restrain the activity of ERK1/2 to avoid toxicities and enable tumor growth. A dual specificity phosphatase, DUSP6, that negatively regulates phosphorylation of (P)-ERK is up-regulated in EGFR- or KRAS-mutant LUAD, potentially protecting cells with mutations in the RAS signaling pathway, a proposal supported by experiments with <italic>DUSP6</italic>-specific siRNA and an inhibitory drug. Targeting DUSP6 or other negative regulators might offer a treatment strategy for certain cancers by inducing the toxic effects of RAS-mediated signaling.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100009326</institution-id><institution>Cancer Research Society</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Lockwood</surname><given-names>William W</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Varmus</surname><given-names>Harold</given-names></name></principal-award-recipient></award-group><award-group id="par-3"><funding-source><institution-wrap><institution>Meyer Cancer Center</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Varmus</surname><given-names>Harold</given-names></name></principal-award-recipient></award-group><award-group id="par-4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100004376</institution-id><institution>Terry Fox Research Institute</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Lockwood</surname><given-names>William W</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf1"><p>The authors declare that no competing interests exist.</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>All data generated or analysed during this study are included in the manuscript and supporting files. Source data files have been provided for Figures 2 and Figure 2-supplemental figure 1 in the Methods section and/or in the text.</p><p>The following previously published datasets were used:</p><p><element-citation id="dataset1" publication-type="data" specific-use="references"><person-group person-group-type="author"><collab>Cancer Genome Atlas Research Network</collab></person-group><year iso-8601-date="2014">2014</year><source>TCGA LUAD</source><ext-link ext-link-type="uri" xlink:href="http://www.cbioportal.org/">http://www.cbioportal.org/</ext-link><comment>PMID, 25079552</comment></element-citation><element-citation id="dataset2" publication-type="data" specific-use="references"><person-group person-group-type="author"><collab>Gazdar A</collab><collab>Girard L</collab><collab>Stephen L</collab><collab>Wan L</collab><collab>Zhang W</collab></person-group><year iso-8601-date="2017">2017</year><source>Expression profiling of 83 matched pairs of lung adenocarcinomas and non-malignant adjacent tissue</source><ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE75037">https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE75037</ext-link><comment>NCBI Gene Expression Omnibus, GSE75037</comment></element-citation><element-citation id="dataset3" publication-type="data" specific-use="references"><person-group person-group-type="author"><collab>Nevins JR</collab></person-group><year iso-8601-date="2005">2005</year><source>Oncogene Signature Dataset</source><ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE3151">https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE3151</ext-link><comment>NCBI Gene Expression Omnibus, GSE3151</comment></element-citation></p></sec><supplementary-material><ext-link xlink:href="elife-33718-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>